Eikon Therapeutics (EIKN) stock
EIKN · Eikon Therapeutics Inc. · NASDAQ
- Market cap
- $257.9M
- Shares out
- 54.2M
What is the latest news on EIKN stock?
Internally-derived candidate EIK1006 targets wild-type androgen receptor and clinically relevant variants implicated in resistance to conventional prostate cancer therapiesInitial clinical data from Phase 1/2 study expected in second half of 2027 MILLBRAE, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (NASDAQ:EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced U.S. Food and Drug Administration clearance to proceed for the Investigational New Drug (IND) application to evaluate EIK1006 for the treatment of advanced metastatic prostate cancer. Eikon plans t
All EIKN newsWhen does Eikon Therapeutics report earnings?
The latest Eikon Therapeutics earnings release came out on Nov 12, 2026: Eikon Therapeutics Reports Third Quarter 2026 Financial Results and Provides Clinical Updates.
EIKN earnings historyWho owns the most EIKN stock?
FMR LLC was the largest reported holder of EIKN at the end of Q2 2026, with 4,993,906 shares worth $65.2 million. Next came BlackRock, Inc. ($55.9 million) and Foresite Capital Management IV, LLC ($25.4 million). In all, 77 institutions reported $344.3 million of EIKN in their 13F filings.
All EIKN fund holdersAre insiders buying or selling EIKN?
Insiders are buying. In the last 90 days 1 insider bought $1.0 million of EIKN in trades reported on Form 4. The latest: Column Group IV GP, LP bought $1.0 million, reported on Sep 8, 2026.
EIKN insider tradesLatest news
25 items- PREikon Therapeutics Announces Clearance to Proceed with First-in-Human Phase 1/2 Study for Novel Androgen Receptor Antagonist EIK1006 in Advanced Metastatic Prostate CancerInternally-derived candidate EIK1006 targets wild-type androgen receptor and clinically relevant variants implicated in resistance to conventional prostate cancer therapiesInitial clinical data from Phase 1/2 study expected in second half of 2027 MILLBRAE, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (NASDAQ:EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced U.S. Food and Drug Administration clearance to proceed for the Investigational New Drug (IND) application to evaluate EIK1006 for the treatment of advanced metastatic prostate cancer. Eikon plans t
- SECSEC Form 10-Q filed by Eikon Therapeutics Inc.10-Q - Eikon Therapeutics, Inc. (0001861123) (Filer)
- SECEikon Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Eikon Therapeutics, Inc. (0001861123) (Filer)
- PREikon Therapeutics Reports Third Quarter 2026 Financial Results and Provides Clinical UpdatesPresented seven posters at the 2026 European Society for Medical Oncology (ESMO) Congress highlighting progress across the oncology portfolio, including clinical data from Eikon’s PARP1-selective inhibitor and Werner (WRN) helicase inhibitor programs and updated EIK1001 data from TeLuRide-005, a Phase 2 trial in non-small cell lung cancer (NSCLC)Dosed first patient in TeLuRide-008, a registrational Phase 2/3 trial of EIK1001 in combination with pembrolizumab and chemotherapy in NSCLCSubmitted an Investigational New Drug (IND) application for EIK1006, a novel non-lutamide androgen receptor (AR) antagonist with broad activity against wild type and AR variants associated with treatment failure
- PREikon Therapeutics to Participate in Multiple Investor Conferences in NovemberCEO Roger M. Perlmutter, M.D., Ph.D., to participate in Guggenheim 3rd Annual Healthcare Innovation Conference Fireside Chat and JP Morgan Biotech Call seriesCMO Roy Baynes, M.D., Ph.D., to participate in Morgan Stanley Biotech Webcast discussing new data and the evolving synthetic lethality landscape MILLBRAE, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (NASDAQ:EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that Roger M. Perlmutter, M.D., Ph.D., Chief Executive Officer and Board Chair of Eikon Therapeutics, will participate in the JP Morgan Chase
- SECSEC Form 8-K filed by Eikon Therapeutics Inc.8-K - Eikon Therapeutics, Inc. (0001861123) (Filer)
- PREikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology CongressTLR7/8 dual-agonist EIK1001 plus pembrolizumab and chemotherapy in first-line, stage 4 non-small cell lung cancer (NSCLC) demonstrates durable effect in combination with standard-of-care, and a tolerability profile supportive of systemic administration in an outpatient settingWith median follow-up of 12.7 months, objective response rate (ORR) for the squamous cohort was 72% and disease control rate (DCR) was 100%, with a median duration of response of 12.9 months and multiple participants continuing in active follow-upTeLuRide-008, an ongoing adaptive Phase 2/3 trial of EIK1001 in NSCLC, actively enrolling, with a prespecified interim analysis for dose selection anticipated in 2H 2027 MILLB
- SECSEC Form 8-K filed by Eikon Therapeutics Inc.8-K - Eikon Therapeutics, Inc. (0001861123) (Filer)
- PREikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology CongressInitial and updated cohort data from ongoing Phase 1/2 study of highly selective non-brain-penetrant PARP1 inhibitor EIK1003 continue to support potentially differentiated profile of EIK1003 in combination strategies within the PARP inhibitor landscapeInitial results from ongoing Phase 1/2 study of highly selective CNS-penetrant PARP1 inhibitor EIK1004 demonstrate a generally well-tolerated safety profile across multiple dose levels, with minimal Grade 3 or higher hematologic toxicities as of the safety data cutoffPreliminary data for Werner (WRN) helicase inhibitor EIK1005 support continued development as monotherapy and in combination with pembrolizumab, with pharmacokinetic (PK) profile s
- PREikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology CongressPresentations to cover updates across Eikon’s clinical pipeline including: Updated data from TeLuRide-005, an ongoing open-label Phase 2 trial of EIK1001, a TLR7/8 dual-agonist, plus pembrolizumab and histology-appropriate chemotherapy in stage 4 non-small cell lung cancer (NSCLC)Updated cohort data from an ongoing Phase 1/2 study of EIK1003, a highly selective non-brain penetrant PARP1 inhibitor, as monotherapy and in combination with chemotherapy in advanced solid tumorsInitial data from a Phase 1/2 study of EIK1003 in combination with the novel hormonal agent abiraterone in metastatic prostate cancerInitial results from an ongoing Phase 1/2 study of EIK1004, a highly selective CNS-penet
- ANALYSTH.C. Wainwright initiated coverage on Eikon Therapeutics with a new price targetH.C. Wainwright initiated coverage of Eikon Therapeutics with a rating of Buy and set a new price target of $23.00
- PREikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate CancerMILLBRAE, Calif., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (NASDAQ:EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to evaluate EIK1006 for the treatment of advanced metastatic prostate cancer. EIK1006 is a novel androgen receptor (AR) antagonist that is structurally unrelated to currently available lutamide-class antagonists. "The submission of an IND for EIK1006 demonstrates once again that Eikon’s advanced imaging platform can permit the identi
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Eikon Therapeutics Inc.SCHEDULE 13G/A - Eikon Therapeutics, Inc. (0001861123) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Eikon Therapeutics Inc.SCHEDULE 13G/A - Eikon Therapeutics, Inc. (0001861123) (Subject)
- INSIDERLarge owner Column Group Iv Gp, Lp bought $1,031,045 worth of shares (89,200 units at $11.56) (SEC Form 4)4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)
- PREikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific OfficerMILLBRAE, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (NASDAQ:EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the appointment of Ching-Pin ("CP") Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer. Dr. Chang is a physician-scientist and accomplished research leader with more than two decades of experience spanning academic medicine, foundational research, and drug discovery. He joins Eikon from Bristol Myers Squibb, where he most recently served as Vice President, Head of Cardiovascular Discovery Biology and Translational Ph
- PREikon Therapeutics to Participate in Investor Conferences in September 2026MILLBRAE, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (NASDAQ:EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that Roger M. Perlmutter, M.D., Ph.D., Chairman and Chief Executive Officer, and Freddie Bowie, Ph.D., Chief Financial Officer, will participate in two upcoming investor conferences taking place in September: Event:12th Annual Cantor Global Healthcare Conference Location: New York, NYDate & Time: September 10, 2026 at 2:10 pm ETFormat: Fireside Chat Event: The Morgan Stanley 24th Annual Global Healthcare ConferenceLocation: New York, NYDate
- PREikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor FitzgeraldMILLBRAE, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (NASDAQ:EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that its Chairman and Chief Executive Officer, Roger M. Perlmutter, M.D., Ph.D., will participate in a key opinion leader (KOL) event on Thursday, August 20, 2026, at 9:00 AM ET, hosted by Cantor Fitzgerald and featuring Dr. Timothy A. Yap, MBBS, PhD, FRCP, medical oncologist and physician scientist from the University of Texas MD Anderson Cancer Center. Dr. Timothy A. Yap currently serves as Vice President and Head of Clinical Development in
- SECEikon Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Eikon Therapeutics, Inc. (0001861123) (Filer)
- SECSEC Form 10-Q filed by Eikon Therapeutics Inc.10-Q - Eikon Therapeutics, Inc. (0001861123) (Filer)
- SECEikon Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Eikon Therapeutics, Inc. (0001861123) (Filer)
- PREikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical UpdatesEikon announced seven abstracts accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026 highlighting progress across Eikon’s oncology portfolio, including clinical updates for EIK1001 and EIK1003 and initial clinical findings for EIK1004 and EIK1005Presented data at the American Society for Clinical Oncology (ASCO) 2026 Annual Meeting demonstrating encouraging activity of EIK1001 combined with pembrolizumab and histology-appropriate chemotherapy for the front-line treatment of patients with advanced NSCLC in the TeLuRide-005 Phase 2 trial, and preliminary evidence that the PARP1-selective inhibitor EIK1003 could be safely combined with full-dose paclitaxel
- PREikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced MelanomaSelected 0.60 mg/m2 as the single dose for the TeLuRide-006 study going forward for patients randomized to EIK1001 treatment, in accord with a recommendation of the independent Data Monitoring Committee (DMC) following a prespecified analysisDMC recommended that the TeLuRide-006 study continue as planned in all other respects MILLBRAE, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (NASDAQ:EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the selection of a dose of 0.60 mg/m2 that will be employed in future for all patients randomized to receive EIK1001 in
- PREikon Therapeutics Appoints Johnny Bennett, Ph.D. to its Scientific Advisory BoardMILLBRAE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (NASDAQ:EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the addition of Johnny Bennett, Ph.D. to its Scientific Advisory Board. Dr. Bennett currently serves as Vice President, and Head of Discovery Chemistry at Merck Research Laboratories. Eikon has a long-standing relationship with Merck (known as MSD outside of the US and Canada). Merck has provided their anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), for registration-enabling trials involving EIK1001, Eikon’s systemically administered TLR7/8 dua
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Eikon Therapeutics Inc.SCHEDULE 13G/A - Eikon Therapeutics, Inc. (0001861123) (Subject)
EIKN rankings
- Other9(53%)
- SEC Filings4(24%)
- Leadership1(6%)
- Insider1(6%)
- Analyst1(6%)
- Earnings1(6%)
Eikon Therapeutics Inc. (EIKN) is a Biotechnology: Biological Products (No Diagnostic Substances) company listed on NASDAQ. In the last 30 days Quantisnow tracked 9 wire items for EIKN, including 4 press releases and news items, 4 SEC filings and 1 earnings update. The most recent was published Nov 17, 2026.
EIKN FAQ
6 questionsWhere does EIKN stock trade?
Eikon Therapeutics Inc. (EIKN) is listed on NASDAQ.What sector and industry is EIKN in?
Eikon Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Eikon Therapeutics Inc. go public?
Eikon Therapeutics Inc. (EIKN) completed its IPO in 2026.What are analysts saying about EIKN?
Eikon Therapeutics Inc. has had 7 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $23.00 price target on 2026-10-16. Recent price targets range from $7.00 to $34.00.What companies are similar to EIKN?
Notable peers in the same industry include EXEL (Exelixis Inc.), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.), MRNA (Moderna Inc.), GILD (Gilead Sciences Inc.). Compare EIKN side-by-side with any of them on Quantisnow.How can I track EIKN on Quantisnow?
Quantisnow aggregates Eikon Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow EIKN to receive live email and push alerts on every new disclosure.
Is something on this page wrong, or out of date? Request a change